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Abstract  
Objective: To determine the additional diagnostic value of diffusion-weighted imaging (DWI) and 
dynamic contrast-enhanced (DCE) imaging in men requiring a repeat biopsy within the PICTURE 
study. 
Patients and Methods: PICTURE was a paired-cohort confirmatory study in which 249 men who 
required further risk stratification following a previous non-MRI guided TRUS biopsy underwent a 3-
Tesla mpMRI consisting of T2W, DWI and DCE followed by transperineal template prostate mapping 
(TPM) biopsy. Each mpMRI was reported using a LIKERT score in a sequential blinded manner to 
generate scores for T2W, T2W+DWI and T2W+DWI+DCE. Area under the receiver operating 
characteristic (AUROC) fanalysis was performed to compare the diagnostic accuracy of each 
combination. The threshold for a positive mpMRI was set as a LIKERT score >/=3. Clinically significant 
prostate cancer was analysed across a range of definitions including UCL/Ahmed Definition 1 
(primary definition), UCL/Ahmed Definition 2, any Gleason >/=3+4 and any Gleason >/=4+3.  
 
Results: Of 249, sequential MRI reporting was available for 246. There was a higher rate of equivocal 
lesions (44.6%) using T2W alone compared to the addition of DWI (23.9%) and DCE (19.8%). Using 
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overall accuracy between T2W at AUROC 0.74 (95% CI 0.68-0.80), T2W+DWI at 0.76 (95% CI 0.71-
0.82) and T2W+DWI+DCE at 0.77 (95% CI 0.71-0.82) (p=0.55). The AUROCs remained comparable 
using other definitions of clinically significant disease including UCL/Ahmed 2 (p=0.79), Gleason 
>/=3+4 (p=0.53) and Gleason >/=4+3 (p=0.53).  
Conclusions: Using a 3T MRI, a high level of diagnostic accuracy can be achieved using T2W as a 
single parameter in men with a prior biopsy. However, such a strategy can lead to a higher rate of 
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Introduction 
Multi-parametric magnetic resonance imaging (mpMRI) has become an important test for the 
detection and ruling out of clinically significant prostate cancer (1-3). There has been increased 
standardisation of the sequences following the technical parameters described in expert consensus 
guidelines (4, 5). The standard acquisition parameters combine anatomical T1-weighted (T1W) and 
T2-weighted (T2W) imaging with functional sequences. The standard functional sequences are 
diffusion weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging which provide 
additional information on cellular density and tissue vascularity. 
 
Uncertainty remains on whether this entire combination of sequences is necessary to rule-out and 
detect clinically significant prostate cancer. In early guidelines there was a similar level of 
importance given to each T2W, DWI and DCE sequences (6). The current version of the Prostate 
Imaging Reporting-Data System (PI-RADSv2) has limited the role of DCE to a binary score which can 
only differentiate equivocal lesions in the peripheral zone (PZ) (7). It also recommends dominant 
sequences based on zonal anatomy so that DWI is dominant in the PZ and T2W is dominant in the 
transition zone (TZ). Recent systematic reviews have indicated that DCE may not be necessary (8, 9) 
supported by results from paired cohort studies from expert centres (10, 11). 
 
This study evaluates the diagnostic accuracy of combining T2W with functional sequences on a 3 
Tesla (3T) MRI against transperineal prostate template mapping (TPM) biopsy within the PICTURE 
trial. TPM biopsy provides a robust reference standard for clinically significant prostate cancer due 
to the fixed 5mm sampling of the entire prostate. This approach minimises the methodological 
limitations from alternative reference tests such as transrectal ultrasound-guided (TRUS) 10-12 core 
systematic non-MRI guided biopsy which have an inherent random error and whole-mount radical 
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Patients and Methods 
Study Design: The PICTURE trial was a paired-cohort validating confirmatory study designed to 
provide level 1 evidence on the diagnostic accuracy of mpMRI in men who required further biopsy. 
The study was approved by the National Research Ethics Committee London (reference 11/LO/1657) 
and the full trial protocol has been previously published (12). The primary outcomes on accuracy of 
mpMRI, Prostate Histoscanning and image-targeted biopsies were recently reported (13-15). This 
PICTURE analysis is Standards for Reporting Diagnostic Accuracy (STARD) compliant(16). 
Participants: Participants were recruited in outpatient clinic and were eligible for enrolment if they 
had undergone prior TRUS-biopsy and been advised as part of standard of care to undergo a repeat 
biopsy for further risk stratification. Participants were excluded if they had previous treatment for 
prostate cancer; a contraindication to MRI or artefact which would reduce MRI quality; a prostate 
gland volume >/=80ml or other medical conditions meaning they were unable to have general or 
regional anaesthesia.  
Imaging Protocol: mpMRI was performed using a 3T scanner with a pelvic-phased array coil. The 
acquisition protocol consisted of T1W and T2W sequences, DWI with high b-value (b=2000) and 
apparent diffusion coefficient (ADC) map using multiple b-values (b=0,150,500,1000) and DCE with 
gadopentetate dimeglumine (Magnevist, Bayer AG, Leverkusen, Germany). The full acquisition 
parameters are listed in the supplementary appendix.  
 
Image Interpretation: MRI scans were reported in a sequential blinded fashion so that three sets of 
reports were generated; T2W alone, T2W+DWI and T2W+DWI+DCE. Reporting was completed in a 
single session with each sequential report locked after being issued. The reporting was completed by 
a board-certified radiologist with over 10 years of experience in prostate MRI interpretation and 
reporting a high volume of MRIs per annum (>1500 scans/year). To assess inter-observer agreement, 
50 (20%) of mpMRI consisting of all sequences were randomly selected for re-reporting by a second 
expert radiologist blinded to the original reports.  
A 5-point Likert Assessment System was used to rate the likelihood of clinically significant disease as 
highly unlikely (1), unlikely (2), equivocal (3), likely (4) or highly likely (5). This scoring system has 
been prospectively validated in the PROMIS trial(1) and has been recommended for use by our 
national consensus meeting(17). Comparative studies have shown that it provides similar results to 
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Reference test: All participants underwent TPM biopsy irrespective of the findings on mpMRI. 
Participants were blinded to the mpMRI results to reduce selection bias and increase non-
compliance with TPM biopsy. The mapping procedure followed a pre-defined protocol in which 
biopsy cores were taken every 5mm using a brachytherapy grid. Additional targeted cores could also 
be taken within the biopsy protocol which were processed and reported separately. As per the 
original analysis plan and the primary outcomes of mpMRI validation (13) only the TPM biopsies 
were used in this report.   All biopsies were reported in accordance with the 2005 International 
Society of Urological Pathology (ISUP) recommendations (20) by one of two expert uropathologists 
blinded to the mpMRI images. Any negative biopsy was double reported as part of a quality control 
process.  
Outcomes: The definition of clinically significant disease was set using validated criteria which have 
been developed for TPM biopsy (21). The primary definition (UCL/Ahmed definition 1) was the 
presence of dominant Gleason pattern 4 or greater and/or a cancer core length (CCL) involvement of 
>/=6mm of any Gleason score. The secondary definitions were a) UCL/Ahmed 2 (any Gleason score 7 
and/or CCL involvement of >/=4mm of any Gleason score), b) any Gleason >/=3+4 and c) any 
Gleason >/=4+3.  
 
Statistics 
The study sample size had been calculated based on the negative predive value (NPV) of mpMRI as 
the primary objective of the PICTURE trial (12), so the current manuscript is not specifically powered 
to compare the additional diagnostic value of functional sequences and T2W alone. Descriptive 
statistics were used for baseline characteristics, distribution of LIKERT scores and cancer detection 
rates. The index test was considered positive for an mpMRI score of 3 or greater in any sector. 
Sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) were 
calculated for each of the three sequences with binomial 95% confidence intervals, with a score of 3 
or above designated a suspicious/positive MRI. Receiver–operator curves (ROC) were constructed 
and DeLong’s test was used to compare the area under the ROC (AUROC) (22). 
The inter-observer agreement was calculated using weighted kappa and proportion of agreement 
and assessed using AUROC. The weighted kappa allows for the magnitude of the disagreements to 
be taken into account. The weighting system used resulted in the weights 0.75, 0.5, 0.25 and 0 for 









STATA version 11.0 software (Stata Corporation, College Station) with any tests of significance using 
2-sided p=0.05 as the threshold for statistical significance.  
Results 
Baseline Characteristics 
A total of 330 participants were enrolled into the study. There were 81 withdrawals, 249 participants 
underwent both mpMRI and TPM-biopsy and 246 had a full set of sequential mpMRI reports (Figure 
1 and Table 1). Previous TRUS biopsy results included no cancer in 76 (30.5%), Gleason 6 in 121 
(48.6%) and low volume Gleason 7 in 52 (21.1%).  
A median (IQR) 49 (40-50) cores were taken at TPM-biopsy. Any cancer was detected on TPM-biopsy 
in 209 (83.9%) of 249. Using definition 1, clinically significant cancer was detected on TPM-biopsy in 
103 (41%) of 249 (Table 2). A non-suspicious MRI (LIKERT score </=2) occurred for T2W in 18.5%, 
TW2+DWI 12.6% and TW2+DWI+DCE 8.9% (Figure 2).  
 
Diagnostic Accuracy 
For the primary definition, T2W alone had sensitivity 96% (90-99), specificity 29% (22-37), positive 
predictive value (PPV) 49% (42-56) and negative predictive value (NPV) 91% (79-98).  For T2W+DWI, 
sensitivity was 96% (90-99), specificity 29% (22-37), (PPV) 49% (42-56) and (NPV) 91% (79-98).  For 
T2W+DWI+DCE, sensitivity was 96% (90-99), specificity 29% (22-37), PPV 49% (42-56) and NPV 91% 
(79-98) (Table 3). The diagnostic performance for each set of sequences was evaluated for other 
definitions of clinical significance on TPM-biopsy as presented in Table 4.  
 
Overall accuracy for definition 1, as assessed by area under the receiver operating characteristic 
curve (AUROC), for T2W, T2W+DWI and T2W+DWI+DCE were 0.74 (95% CI 0.68-0.80), 0.76 (95% CI 
0.71-0.82) and 0.77 (95% CI 0.71-0.82), respectively (p=0.55) (Figure 3). There were no significant 
differences in overall accuracy when comparing AUROC for other definitions of clinically significant 
disease (Tables 5) (Figure 4).  
Inter-observer variability 
The weighted agreement on the double-read of the full mpMRI sequence was 87.0% (K=0.52, 
standard error [se] =0.10) indicating good agreement. When the mpMRI scores for each reporter 









terms of AUROC analyses (reporter one AUROC 0.76 [0.63-0.90] versus reporter two 0.75 [0.61-
0.89]). 
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Discussion 
In summary, our PICTURE study results showed that the added diagnostic value of functional 
sequences was marginal using a 3T MRI scanner in men requiring a repeat biopsy. To our knowledge, 
this is the first study that presents the diagnostic accuracy of combining T2W and functional 
sequences against TPM-biopsy as an accurate reference standard. The overall accuracy of mpMRI 
was high across all combinations of sequences and definitions of clinically significant disease. 
In this study, an abbreviated MRI protocol could still function as a triage test to rule-out clinically 
significant prostate cancer in men requiring repeat biopsies, but the number of men avoiding 
biopsies as a result of using more sequences decreased from 18.5% (T2W alone) to 12.6% 
(T2W+DWI) and 8.9% (T2W+DWI+DCE). The number of biopsy would increase but without adding 
significant utility as no additional cases of significant disease were identified with DWI and only one 
extra case was identified with DCE. 
Rather surprisingly, our findings suggest that it may be feasible using T2W images alone on a 3T MRI 
to achieve a high level of diagnostic accuracy. Similar findings have been previously reported by 
Mertan et al (23) in a prospective study of 62 patients which also used a 3T MRI. The findings of both 
studies should be interpreted cautiously as the results are derived from single high-volume centres 
using a 3T MRI scanner in a patient population that does not represent biopsy-naïve men. In 
contrast, the majority of previous studies have demonstrated improved accuracy for detection of 
prostate cancer using functional sequences in combination with T2W imaging (24, 25). 
Our study serves to highlight that specific sequences might be safely omitted without impacting 
diagnostic accuracy. With recent guidelines issued by NICE in the UK (26) as well as the European 
Association of Urology (27), there will be rapid uptake of pre-biopsy mpMRI, resulting in increasing 
pressures on limited capacity. Endeavours that shorten the sequences without significantly 
compromising the triage role of pre-biopsy MRI and detection rates of clinically significant prostate 
cancer might improve on cost-efficiency and throughput.  
 
There is reason to be cautious in moving towards a stripped-down version of only T2W. Although the 
supplementary information provided by DWI and DCE did not improve AUROC, there was a shift in 
the distribution of LIKERT scores. The functional sequences had a useful role upgrading LIKERT 3 
lesions and improving the reporter’s scoring confidence for other lesions (Figure 5). The addition of 
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increase in LIKERT 5 lesions from 12.0% to 37.9%. This shift has also been observed in similar studies 
using PIRADSv2 where DCE has a role distinguishing equivocal lesions in the PZ (28). It has been 
suggested that the higher proportion of equivocal lesions could be addressed by only performing the 
additional sequences in those cases where such a lesion is identified. However, this would require 
scans to be immediately reported or the patient to return for a second scan at a later date. 
 
Given our findings, a protocol using T2W and DWI may be a reasonable approach to balance the 
number of men avoiding an immediate biopsy and the reduction in equivocal lesions. The removal of 
contrast has advantages in terms of patient acceptability as well as reducing scanning time. The 
safety of gadolinium-based contrast has been questioned following reports that it can form 
depositions within the dentate nucleus and globus pallidus(29).  
 
This approach is supported by recent systematic reviews and meta-analyses comparing standard 
mpMRI with biparametric MRI (bpMRI) defined as consisting of T2W and DWI sequences without 
DCE. In this meta-analysis the pooled summary statistics had no significant difference in sensitivity 
(mpMRI: 86%, 95% confidence interval [CI] 81-90; bpMRI: 90%, 95% CI 83-94) or specificity (mpMRI: 
73%, 95% CI 64-81; bpMRI: 70%, 95% CI 42-83) with the summary AUROCs being comparable for 
mpMRI (0.87) and bpMRI (0.90) (8). Subsequent to this, van der Leest et al (10) have shown that 
sensitivity for high-grade prostate cancer for both bpMRI and mpMRI was 95% (95% CI 91-97%) with 
specificity 69% (95% CI 64-73%). In this study biopsy could be avoided in 49% for the bpMRI and 
mpMRI protocol. The recently published Danish BIDOC paired cohort clinical utility study in over one 
thousand men has also shown that bpMRI has good performance characteristics but was unable to 
compare their findings to mpMRI (11). 
Our study has several limitations. First, these findings relate to an expert centre using a 3T MRI 
producing high-quality T2W images. We acknowledge that this limits the reproducibility of our 
findings given that 1.5T is commonly used. Second, this represents a whole-gland analysis and 
regional analysis differentiating PZ and TZ may highlight an added value of DWI and/or DCE. Third, 
the study had a heterogeneous patient population and we acknowledge that these findings may not 
relate to a biopsy-naïve population. Fourth, TPM is not a suitable reference standard for evaluation 
of extraprostatic extension so the impact of bp-MRI on staging has not been assessed in this study. 
Last, and importantly, we cannot test the clinical utility of a bpMRI pathway compared to a mpMRI 
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This is necessary since radiologists may score differently when they know that patients have not had 
the DCE sequences. 
In conclusion, the present study showed that a high level of diagnostic accuracy can be achieved 
using T2W as a single parameter with a 3T MRI in men with a prior biopsy. However, such a strategy 
can lead to a higher rate of equivocal lesions so a protocol including T2W and DWI may offer the 
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Table 1: Characteristics of participants at baseline 
Characteristic Participants (n = 249) 
Age, years (SD) 62 (7.0) 
PSA (ng/ml), Median (IQR) 6.8 (4.8-9.8) 
Prostate volume, median (IQR) 37.0  (26.8-50.0)
Number of previous biopsies, median (IQR) 1 (1-2) 
Previous TRUS biopsy result (%)  
- Benign 
- Gleason 3+3 
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Table 2: Histological Characteristics on Transperineal Template Mapping biopsy 
Characteristic Participants (n = 249) 
TPM biopsy outcome (%) 
Benign 
Gleason score
    3+3 
    3+4 
    4+3 
    4+4 








Maximum cancer core length 
mm, median (IQR) 
4 (2-7) 
Cores positive for cancer, 
median (IQR) 
6 (2-11) 
Total number of cores, median 
(IQR) 
45 (40-55) 
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Table 3: Diagnostic accuracy of different combinations of MRI sequences using UCL/Ahmed 
Definition 1 for clinically significant cancer 
Sensitivity 
% (95% CI) 
Specificity 
% (95% CI) 
PPV 
% (95% CI) 
NPV 
% (95% CI) 
Primary Definition (UCL/Ahmed 1): Dominant Gleason pattern 4 or greater and/or a 
cancer core length (CCL) involvement of >/=6mm of any Gleason score 
T2W 96 (90-99) 29 (22-37) 49 (42-56) 91 (79-98) 
T2W + DWI 96 (90-99) 19 (13-26) 45 (39-52) 87 (70-96) 
T2W + DWI + DCE 97 (92-99) 13 (8-20) 44 (37-51) 86 (65-97) 
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Table 4: Diagnostic accuracy of different MRI sequences using other definitions of clinically 
significant prostate cancer  
Sensitivity 
% (95% CI) 
Specificity 
% (95% CI) 
PPV 
% (95% CI) 
NPV 
% (95% CI) 
UCL/Ahmed 2: Any Gleason score 7 and/or CCL involvement of >/=4mm of any 
Gleason score 
T2W 92 (87-96) 41 (30-52) 76 (70-82) 72 (57-84) 
T2W + DWI 95 (90-98) 27 (18-38) 73 (66-79) 71 (52-86) 
T2W + DWI + DCE 96 (92-99) 20 (12-30) 71 (65-77) 73 (50-89) 
Any Gleason score >/=3+4 
T2W 93 (88-97)  34 (25-44) 66 (59-72) 78 (64-89) 
T2W + DWI 95 (90-98) 23 (15-32) 63 (56-69) 77 (59-90) 
T2W + DWI + DCE 97 (92-99) 16 (10-24) 61 (54-67) 77 (55-92) 
    
Any Gleason score >/=4+3 
T2W 94 (79-99) 20 (15-26) 15 (10-20) 85 (96-100) 
T2W + DWI 97 (84-100) 14 (10-19) 14 (10-20) 97 (83-100) 
T2W + DWI + DCE 97 (84-100) 10 (6-15) 14 (10-19) 77 (96-100) 
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Table 5: Comparison of Area under receiver operating characteristic curve (AUROC) across 
definitions of clinically significant disease 
AUROC UCL/Ahmed Def 1 
(95% CI) 
UCL/Ahmed Def 2 
(95% CI) 
Gleason >/=3+4  
(95% CI) 
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